Clinical trials: Type Two Diabetes Mellitus
Type 2 Diabetes Mellitus
A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator
The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.
- Trial name
- NCT00760578
- Testing
- Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg
- Where
- 8 sites in United States
- Volunteers
- 86 people
- Sponsor
- Metabolic Solutions Development Company
Type 2 Diabetes Mellitus
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.
This is a Randomized, open-label, single oral dosing, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of CKD-383 and the co-administration of CKD-501, D745, and…
- Trial name
- NCT06483243
- Testing
- Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG
- Where
- South Korea
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus, Type 2, Dyslipidemias
BE Study of Bilayer Combination of Gemigliptin/Rosuvastatin 50/20mg in Comparison to Monolayer Combination.
To evaluate and compare PK/PD, safety and tolerability of monolayer combination of Gemigliptin/Rosuvastatin 50/20mg and bilayer combination of Gemigliprin/Rosuvastatin 50/20mg in healthy adults.
- Trial name
- NCT03867942
- Testing
- Monolayer group, Bilayer group
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- LG Chem
Diabetes, Diabetes Mellitus, Type 1
A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerance, pharmacokinetics (exposure of drug) and pharmacodynamics (effect) of NN1952 as tablets in healthy volunteers and subjects with type…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01028404
- Testing
- NN1952, insulin aspart
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
- Trial name
- SURPASS-EARLY (NCT05433584)
- Testing
- Tirzepatide, Antihyperglycemic medication
- Where
- 90 sites in United States, Argentina and 9 more
- Volunteers
- 780 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus
The main purpose of the VETA trial is to verify the potential beneficial effects of the combination of micronutrients namely Vitamin D3 and K2 in combination with oral antihyperglycemic Empagliflozin in Diabetes Mellitus
- Trial name
- VETA (NCT05417880)
- Testing
- Oral Hypoglycemic Agents,Oral, Voreta, Voreta plus SunnyD PRO
- Where
- Pakistan
- Volunteers
- 340 people
- Sponsor
- Scotmann Pharmaceuticals
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Europe, Oceania, and the United States of America (USA). The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin detemir (IDet) plus insulin aspart…
- Trial name
- BOOST™ (NCT00978627)
- Testing
- insulin degludec/insulin aspart, insulin detemir, insulin aspart
- Where
- 81 sites in United States, Australia and 8 more
- Volunteers
- 548 people
- Sponsor
- Novo Nordisk A/S
Healthy
Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters
This study is designed to assess the effect of one single dose of PF-05175157 on metabolic and cardiopulmonary parameters before, during and after treadmill exercise in healthy volunteers.
- Trial name
- NCT01819922
- Testing
- PF-05175157
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 1 Diabetes Mellitus
A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus
The purpose of this trial is to test if VC-01™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for two years.
- Trial name
- NCT02239354
- Testing
- VC-01™ Combination Product
- Where
- 2 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- ViaCyte
Diabetes, Diabetes Mellitus, Type 2
Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes
This this trial is conducted in Europe. The aim of this trial is to compare glycaemic control of biphasic insulin aspart 30 (BIAsp 30) alone or combined with insulin aspart(IAsp) in patients previously treated with conventional…
- Trial name
- NCT01697631
- Testing
- biphasic insulin aspart 30, insulin aspart
- Where
- 12 sites in Poland
- Volunteers
- 131 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Extension Study for 2993-112
This multicenter, open-label extension study of Protocol 2993-112 is designed to assess long-term glucose control as measured by HbA1c (glycosylated hemoglobin) and to evaluate long-term safety and tolerability in subjects…
- Trial name
- NCT01789957
- Testing
- AC2993
- Where
- 226 sites in United States, Canada
- Volunteers
- 225 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus
Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus
The purpose of this two-part multiple ascending dose study is to evaluate the safety and tolerability of multiple doses of MHS552 in adults with type 1 diabetes mellitus.
- Trial name
- NCT05272059
- Testing
- MHS552
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Diabetes Mellitus, Type 2
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in Japanese participants with type 2 diabetes. The study duration is approximately 58 weeks.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- AWARD-JPN (NCT04809220)
- Testing
- Dulaglutide, Oral antihyperglycemics
- Where
- 44 sites in Japan
- Volunteers
- 591 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes
This trial is conducted in Asia. This is a clinical trial investigating the effectiveness of using Biphasic Insulin Aspart 70/30 in two different treatment regiments for 6 months in subjects with type 2 diabetes, not well…
- Trial name
- NCT00184561
- Testing
- biphasic insulin aspart
- Where
- 8 sites in China
- Volunteers
- 321 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus (T2DM)
To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.
To compare and evaluate the oral bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg film-coated tablets with that of Glyxambi 10 mg/ 5 mg film-coated tablets in healthy, adult, human subjects under fasting conditions.
- Trial name
- NCT07039890
- Testing
- Empagliflozin + Linagliptin filmcoated tablets, Glyxambi film-coated tablets
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Diabetes, Diabetes Mellitus, Type 2
Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects
This trial is conducted in Japan. The aim of this trial is to investigate the bioequivalence of two formulations of biphasic insulin aspart 50 (NN-X14Mix50) in healthy Japanese subjects.
- Trial name
- NCT01527630
- Testing
- biphasic insulin aspart 50
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects
Albiglutide (Alb) is a novel analogue of glucagon-like peptide-1 (GLP-1) has been developed and approved for the treatment of type 2 diabetes mellitus.
- Trial name
- NCT02660736
- Testing
- Albiglutide Liquid Auto-injector, Albiglutide Lyophilized DCC Pen Injector
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type II Diabetes
A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378
A clinical trial to compare and evaluate the safety and pharmacokinetics of CKD-378
- Trial name
- NCT05741437
- Testing
- CKD-378, QD, PO Drug: D745, D150, QD, PO
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes
A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)
A two-part study to demonstrate the bioequivalence of a single dose of the Final Market Image (FMI) of sitagliptin /metformin (50/500 and 50/1000 mg) Fixed-Dose Combination (FDC) tablet and co-administration of a single dose of…
- Trial name
- NCT00961857
- Testing
- sitagliptin phosphate (+) metformin hydrochloride, Comparator: metformin 500 mg, Comparator: sitagliptin
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide
This study will compare insulin lispro protamine suspension (ILPS) and insulin glargine in combination with the patient's oral diabetes medications and exenatide, for their ability to control blood sugar in patients with type 2…
- Trial name
- NCT00560417
- Testing
- Insulin Lispro Protamine Suspension, Insulin Glargine
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 339 people
- Sponsor
- Eli Lilly and Company